<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-18T04:31:25Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/12737" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/12737</identifier><datestamp>2025-10-24T10:27:07Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Brentuximab vedotin compared with historical controls for severe skin involvement in cutaneous systemic sclerosis</dc:title>
   <dc:creator>Fernández Codina, Andreu</dc:creator>
   <dc:creator>Nevskaya, Tatiana</dc:creator>
   <dc:creator>Baron, Murray</dc:creator>
   <dc:creator>Appleton, Christopher Thomas</dc:creator>
   <dc:creator>Cecchini, Matthew</dc:creator>
   <dc:creator>Philip, Amanda</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Fernández-Codina A] Division of Rheumatology, Western University, London, ON, Canada. Division of General Internal Medicine-Windsor Campus, Western University, London, ON, Canada. Grup de Recerca de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Nevskaya T, Appleton CT, Philip A] Division of Rheumatology, Western University, London, ON, Canada. [Baron M] Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, QC, Canada. [Cecchini MJ] Division of Pathology, Western University, London, ON, Canada</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>Anticossos monoclonals - Ús terapèutic</dc:subject>
   <dc:subject>Avaluació de resultats (Assistència sanitària)</dc:subject>
   <dc:subject>Esclerodèrmia - Tractament</dc:subject>
   <dc:subject>Medicaments immunosupressors - Tractament</dc:subject>
   <dc:subject>DISEASES::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Scleroderma, Systemic</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::Other subheadings::/drug therapy</dc:subject>
   <dc:subject>CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/therapeutic use</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome</dc:subject>
   <dc:subject>ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades del tejido conjuntivo::esclerodermia sistémica</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</dc:subject>
   <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/uso terapéutico</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento</dc:subject>
   <dc:description>Severe skin involvement; Cutaneous systemic sclerosis</dc:description>
   <dc:description>Afectació cutània; Esclerosi sistèmica cutània</dc:description>
   <dc:description>Afectación cutánea; Esclerosis sistémica cutánea</dc:description>
   <dc:description>Investigator-initiated study. Seagen provided partial funding and interpretation of the data. Seagen had courtesy access to the final manuscript, without having influence on the final publication.</dc:description>
   <dc:date>2025-03-11T08:58:34Z</dc:date>
   <dc:date>2025-03-11T08:58:34Z</dc:date>
   <dc:date>2025-02</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Fernández-Codina A, Nevskaya T, Baron M, Appleton CT, Cecchini MJ, Philip A, et al. Brentuximab vedotin compared to historical controls for severe skin involvement in cutaneous systemic sclerosis. Rheumatology. 2025 Feb;64(2):888–9.</dc:identifier>
   <dc:identifier>1462-0332</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/12737</dc:identifier>
   <dc:identifier>10.1093/rheumatology/keae460</dc:identifier>
   <dc:identifier>39189988</dc:identifier>
   <dc:identifier>001328852800001</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/12737</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Rheumatology;64(2)</dc:relation>
   <dc:relation>https://doi.org/10.1093/rheumatology/keae460</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Oxford University Press</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>